Skip to main content

View full-text article in PMC

. 2022 Sep 1;14(9):e28683. doi: 10.7759/cureus.28683

Table 4. Sub-group analysis of patients in pregabalin group.

BMI: body mass index; HbA1c: glycated hemoglobin

Parameter		Efficacy		Total	p-value
Parameter		YES	NO	Total	p-value
Age	30-45 years	12 (80.0%)	03 (20.0%)	15 (100.0%)	0.214
	46-60 years	16 (80.0%)	04 (20.0%)	20 (100.0%)
	61-80 years	04 (50.0%)	04 (50.0%)	08 (100.0%)
Gender	male	19 (76.0%)	06 (24.0%)	25 (100.0%)	0.779
Gender	female	13 (72.2%)	05 (27.8%)	18 (100.0%)	0.779
Disease duration	Less than 20 months	23 (74.2%)	08 (25.8%)	31 (100.0%)	0.956
Disease duration	More than 20 months	09 (75.0%)	03 (25.0%)	12 (100.0%)	0.956
HbA1c	≤8	13 (76.5%)	04 (23.5%)	17 (100.0%)	0.803
HbA1c	>8	19 (73.1%)	07 (26.9%)	26 (100.0%)	0.803
BMI	≤23Kg/m²	16 (76.2%)	05 (23.8%)	21 (100.0%)	0.861
BMI	>23kg/m²	17 (73.9%)	06 (26.1%)	23 (100.0%)	0.861